Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Background Most targeted anticancer therapies, as well as cytotoxic and radiation therapies, are encumbered by the development of secondary resistance by cancer cells. Resistance is a complex phenomenon involving multiple mechanisms, including activation of signaling pathways such as phosphatidylino...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology Jg. 71; H. 4; S. 829 - 842
1. Verfasser:	Burris, Howard A.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Berlin/Heidelberg Springer-Verlag 01.04.2013 Springer Springer Nature B.V
Schlagworte:	Animals Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Cancer Research Drug Resistance, Neoplasm Glioblastoma - drug therapy Gynecology. Andrology. Obstetrics Humans Lung Neoplasms - drug therapy Mammary gland diseases Medical sciences Medicine Medicine & Public Health Neoplasms - drug therapy Neurology Oncology Pharmacology. Drug treatments Pharmacology/Toxicology Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - physiology Pneumology Proto-Oncogene Proteins c-akt - antagonists & inhibitors Proto-Oncogene Proteins c-akt - physiology Review Article Signal Transduction - drug effects TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - physiology Tumors Tumors of the nervous system. Phacomatoses Tumors of the respiratory system and mediastinum Resistance Sensitivity Breast cancer PI3K/AKT/mTOR pathway Lung cancer Glioblastoma Antineoplastic agent Breast disease Acquired Bronchopulmonary Malignant glioma Bronchus disease Lung disease Nervous system diseases Enzyme Respiratory disease Transferases Akt protein kinase Malignant tumor 1-Phosphatidylinositol 3-kinase Mammary gland diseases Treatment Central nervous system disease Mammalian target of rapamycin Cancer
ISSN:	0344-5704, 1432-0843, 1432-0843
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!